Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback ...

A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Johnson & Johnson JNJ is set to invest $2 billion in its North Carolina facilities, expanding its U.S. manufacturing ...

Wall Street braced for results from retail giants as rising concerns over inflation cloud the path to an interest rate cut.

The global monoclonal antibody therapeutics market is set to witness a growth rate of ~12% in the next 5 years. Rising ...

Insulin Market to exceed US$ 31.5 Bn by 2035, expanding at 4.1% CAGR, driven by rising diabetes prevalence and growing access to advanced ...

Ascendis Pharma's TransCon platform shows promise, but challenges with rollout, competition, and execution risks lead to a ...

Psoriasis Treatment Market Rising psoriasis prevalence and increasing adoption of biologics are fueling strong growth in the global psorias ...

Wall Street braced for results from retail giants as rising concerns over inflation cloud the path to an interest rate cut.

India's reskilling market is witnessing accelerated growth, driven by the rapid expansion of Global Capability Centres (GCCs) ...

Eli Lilly and Company (NYSE:LLY)’s pipeline has been advancing, thanks to positive study results in oncology and ...